In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novel Clinical Trial Designs In Oncology: An Histology-Independent Approach

Executive Summary

Cancer’s heterogeneity is a leading reason why product development in this therapeutic area is so risky and costly – and why the pharma industry has not yet addressed all needs in the market. Because low-incidence tumors present recruitment challenges and have lower commercial potential than high-incidence ones, they receive less attention from drug developers; meanwhile, new therapies for high-incidence tumors must demonstrate higher efficacy than therapeutic alternatives in order to differentiate themselves.

You may also be interested in...



Finance Watch: Denali, Avidity And Others Chase Big Money Via Private Placements

Public Company Edition: Denali, Crinetics and Ocular Therapeutix grossed $500m, $350m and $325m, respectively, in private placements ahead of data readouts. Also, Viking raised $550m after its positive Phase II obesity data and Abingworth invested $210m in Gilead’s Trodelvy NSCLC trials.

'There Is Work To Do:' Sean Salmon Discusses Medtronic's Recent Hard-Won Cardio Breakthroughs

Medtech Insight caught up with Sean Salmon, the president of Medtronic's cardiovascular business, to talk about the long-awaited FDA approval of the Simplicity Spyral renal denervation system, recent approvals of the PulseSelect pulsed field ablation system and extravascular ICD, and the company's plans for transcatheter aortic valve replacement.

Bayer Consumer Health Names New President In Surprise Move

Heiko Schipper is departing for Unilever with Bayer Consumer Health promoting Julio Triana to take over just days before a capital markets day which will set the future direction of the business.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV004217

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel